Introduction & Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in patients with T2D. We have assessed the diagnostic performance of non-invasive tests (NITs) and pathways recommended by AASLD guidelines in diabetology.

Methods: Interim analysis from a multicenter prospective study including 568 patients with T2D and MASLD, age 40-80 years, BMI <40 kg/m2 from 4 French diabetes clinics between Oct. 2020 and Oct. 2023. All participants had a detailed liver assessment: Fibrotest, FibroMeter, FIB-4, NFS, ELF and transient elastography (TE) by FibroScan. A low/high risk of AF was defined by a hierarchical composite criterion Fig.

Results: The characteristics were: hypertension: 71%, male 58%, mean age: 60.5 years and BMI: 32.1 kg/m2. Overall, 19% had intermediate/high risk of AF including 10% at high risk. The AUROCs of NITs for the detection of high risk AF were: NFS: 0.70, FIB-4: 0.79, Fibrometer: 0.72, Fibrotest: 0.77, ELF: 0.82. AASLD pathway using ELF classified 81.5% at low risk with 9.4% false negative (FN); 18.5% needed hepatology care with 9.1% true positive (TP). Pathway using TE classified 85.4% at low risk with 5.1% FN; 14.6% needed hepatology care with 13.3% TP (Fig).

Conclusion: Recommended AASLD pathways have a good diagnostic performance in diabetology to identify AF and the use of TE is preferable depending on availability.

graphic
View largeDownload slide
Disclosure

C. Caussy: Other Relationship; Echosens, E-scopics, Novo Nordisk. Consultant; Lilly Diabetes. Other Relationship; Gilead Sciences, Inc. Consultant; GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp. Advisory Panel; Corcept Therapeutics. B. Vergès: Consultant; Lilly Diabetes, Novo Nordisk A/S. Advisory Panel; Recordati. Consultant; AstraZeneca, Sanofi. D. Leleu: None. L. Duvillard: None. A. Abichou-Klich: None. B. Segrestin: None. S. Bin: None. A. Rouland: Other Relationship; Lilly Diabetes, Sanofi, Novo Nordisk. D. Delaunay: None. S. Hadjadj: Consultant; AstraZeneca. Research Support; Asten Santé, Air Liquide. Consultant; Bayer Inc., Boehringer-Ingelheim, Eli Lilly and Company. Research Support; LVL, Nestlé Health Science. Consultant; Novo Nordisk. Board Member; Valbiotis. Consultant; Sanofi. Research Support; Vitalaire. C. Primot: None. J. Petit: None. S. Charrière: Other Relationship; Novo Nordisk, Lilly Diabetes. Consultant; biomarin. Other Relationship; Amgen Inc., Novartis AG, Amarin Corporation. P. Moulin: Other Relationship; Novo Nordisk, Ionis Pharmaceuticals, Sanofi. Advisory Panel; ulktragenix. M. Levrero: Other Relationship; AbbVie Inc., Akero Therapeutics, Inc., Bristol-Myers Squibb Company, CSL Behring, Gilead Sciences, Inc., Inventiva Pharma, Madrigal Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. Research Support; Roche Diagnostics. Advisory Panel; Roche Pharmaceuticals. B. Cariou: Speaker's Bureau; Abbott. Board Member; Air Liquide. Speaker's Bureau; Amgen Inc. Board Member; Eli Lilly and Company. Consultant; Novartis Pharmaceuticals Corporation, Novo Nordisk. Speaker's Bureau; Sanofi. Board Member; Ultragenyx. Speaker's Bureau; AstraZeneca. E. Disse: Board Member; Novo Nordisk. Consultant; Novo Nordisk, Lilly Diabetes, Sanofi, Rhythm Pharmaceuticals, Inc., Johnson & Johnson Medical Devices Companies.

Funding

IRS Grant form Gilead Inc

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.